3-[(4-hydroxycarbamoyltetrahydropyran-4-yl)-(4-phenoxybenzenesulfonyl)amino]-propionic acid ethyl ester | 332049-53-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(4-hydroxycarbamoyltetrahydropyran-4-yl)-(4-phenoxybenzenesulfonyl)amino]-propionic acid ethyl ester
• 英文别名: Ethyl 3-[[4-(hydroxycarbamoyl)oxan-4-yl]-(4-phenoxyphenyl)sulfonylamino]propanoate
• CAS: 332049-53-3
• 化学式: C₂₃H₂₈N₂O₈S
• 分子量: 492.55
• InChiKey: VSJYBCNCYFOGJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders
  申请人：Pfizer Products Inc.

  公开号：EP1088550A1

  公开（公告）日：2001-04-04

  The present invention relates to a method of using a compound of the formula (I): wherein A, X1, X2, and Q are as defined herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.

  本发明涉及一种使用式（I）化合物的方法： 其中 A、X1、X2 和 Q 如本文所定义，其药学上可接受的盐，或其药物组合物，用于治疗外周或中枢神经系统的疾病、病症或紊乱，包括但不限于阿尔茨海默病、中风/脑缺血、头部创伤、脊髓损伤、多发性硬化症、肌萎缩性脊髓侧索硬化症、亨廷顿氏病、帕金森氏病、偏头痛、脑淀粉样血管病、艾滋病、老年性认知功能衰退、轻度认知功能障碍和朊病毒疾病。
• Aryloxyarylsulfonylamino hydroxamic acid derivatives
  申请人：Pfizer Products Inc.

  公开号：EP1415984A1

  公开（公告）日：2004-05-06

  A compound of the formula (I) or the pharmaceutically acceptable salts thereof, wherein R1 is (C1-C6)alkyl; R2 is (C1-C6)alkyl; or R1 and R2 taken together with the carbon atom to which they are attached form a ring selected from (C5-C7)cycloalkyl, 4-tetrahydropyranyl and 4-piperidinyl; R3 is hydrogen or (C1-C6)alkyl; and Y is a substituent of any of the carbon atoms of the phenyl ring capable of supporting an additional bond, independently selected from hydrogen, fluoro, chloro, trifluoromethyl, (C1-C6)alkoxy, trifluoromethoxy, difluoromethoxy and (C1-C6)alkyl.

  一种式(I)化合物或其药学上可接受的盐，其中 R1 是(C1-C6)烷基；R2 是(C1-C6)烷基；或 R1 和 R2 与它们所连接的碳原子一起形成选自(C5-C7)环烷基、4-四氢吡喃基和 4-哌啶基的环；R3 是氢或(C1-C6)烷基；以及 Y 是苯基环上任何一个碳原子的取代基，该取代基能够支持一个额外的键，独立选自氢、氟、氯、三氟甲基、(C1-C6)烷氧基、三氟甲氧基、二氟甲氧基和(C1-C6)烷基。
• ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES
  申请人：Pfizer Products Inc.

  公开号：EP1003720A1

  公开（公告）日：2000-05-31
• US6417229B1
  申请人：——

  公开号：US6417229B1

  公开（公告）日：2002-07-09
• [EN] ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES<br/>[FR] DERIVES DE L'ACIDE ARYLOXYARYLSULFONYLAMINO HYDROXAMIQUE
  申请人：PFIZER PRODUCTS INC.

  公开号：WO1999007675A1

  公开（公告）日：1999-02-18

  (EN) A compound of formula (I) or the pharmaceutically acceptable salts thereof, wherein R1 is (C1-C6)alkyl; R2 is (C1-C6)alkyl; or R1 and R2 taken together with the carbon atom to which they are attached form a ring selected from (C5-C7)cycloalkyl, 4-tetrahydropyranyl and 4-piperidinyl; R3 is hydrogen or (C1-C6)alkyl; and Y is a substituent of any of the carbon atoms of the phenyl ring capable of supporting an additional bond, preferably from 1 to 2 substituents (more preferably one substituent, most preferably one substituent in the 4-position) on the phenyl ring, independently selected from hydrogen, fluoro, chloro, trifluoromethyl, (C1-C6)alkoxy, trifluoromethoxy, difluoromethoxy and (C1-C6)alkyl.(FR) L'invention porte sur un composé de formule (I), ou ses sels pharmacocompatibles, dans laquelle: R1 est (C1-C6) alkyle, R2 est (C1-C6) alkyle, ou R1 et R2 pris ensemble avec un atome de carbone auquel ils sont liés forment un cycle sélectionné parmi (C5-C7) cycloalkyle, 4-tétrahydropyranyle et 4-pipéridinyle; R3 est hydrogène ou (C1-C6) alkyle, et Y est en substituant de l'un des atomes de carbone du cycle phényle capable de porter une liaison additionnelle de préférence de deux substituants (ou mieux, un substituant ou mieux encore un substituant en position 4) sur le cycle phényle, sélectionné indépendamment parmi hydrogène, fluoro, chloro, trifluorométhyle, (C1-C6) alkoxy, trifluorométhoxy, difluorométhoxy, et (C1-C6) alkyle.